Moderna Says Updated COVID Vaccine is Effective Against Newer Variant

Reuters | By Patrick Wingrove

WASHINGTON — Moderna on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections.

The company said its shot generated an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86, which is being tracked by the World Health Organization and the U.S. Centers for Disease Control and Prevention.

"We think this is news people will want to hear as they prepare to go out and get their fall boosters," Moderna's head of infectious diseases Jacqueline Miller said, adding that the data should also help reassure regulators.

The CDC has previously indicated that BA.2.86 may be more capable of causing infection in people who previously had COVID or were vaccinated with previous shots. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the dominant variant through most of 2023 and the target of the updated shots.

Moderna said it had shared the new finding on its vaccine with regulators and submitted it for peer-review publication. The retooled shot has yet to be approved by the U.S. Food and Drug Administration but is expected to be available later this month or in early October.

Read Full Article